Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IMW 2021 | MRD: its role and importance for myeloma treatment

Katja Weisel, MD, of the University Medical Center Hamburg-Eppendorf, Hamburg, Germany, discusses the role of measurable residual disease (MRD) in the treatment of myeloma and its importance for patients. Dr Weisel also explains that MRD assessment results should be considered with caution as this is not the only measurement and is not definitive of complete remission or relapse. This interview took place during the 18th International Myeloma Workshop (IMW 2021) congress.

Disclosures

Katja Weisel, MD, has received institutional grant support from Amgen, BMS/Celgene, GSK and Sanofi; and has received honoraria from AbbVie, Amgen, Adaptive Biotech, BMS/Celgene, Janssen, GSK, Karyopharm, Novartis, Oncopeptides, Pfizer, Roche Pharma, Takeda and Sanofi.